One of semaglutide's inactive ingredients has been linked to changes in gut bacteria and inflammatory markers. | Drug Discovery And Development ...

Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and ...

A pill version of the popular GLP-1 weight-loss drug Wegovy has been green-lit for use in the U.S. Here’s what that means for health care A new study finds that people who quit weight-loss medications ...

A NOVEL non-peptide glucagon-like peptide-1 receptor agonist pill is more effective for weight loss than oral semaglutide in patients with Type 2 diabetes, a 2026 Phase III trial ...

Novo Nordisk (NVO) stock is in focus as Strive Pharmacy, a pharmacy partner for Hims & Hers (HIMS) plans to offer a compounded version of Wegovy pill. Read more here.

The new pill form of popular GLP-1 drugs contains a compound that could cause troubling side effects. Historically, ...

Orforglipron, a novel oral nonpeptide GLP-1 receptor agonist (RA), led to a greater reduction in A1c and more significant weight loss compared to oral semaglutide in patients with type 2 diabetes (T2D ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.

The study suggests that the novel compound may offer superior glycaemic control and weight reduction compared with current ...

Cost-effectiveness is highly price-sensitive; lower U.S. prices, particularly approaching European levels, shift semaglutide toward favorable value rather than a binary go/no-go determination. Patient ...